{"entity":{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","aka":["Leucovorin Calcium","Folinic acid","Calcium folinate","Levoleucovorin (Fusilev, Khapzory)"],"tldr":"Leucovorin is not a cancer drug in itself: it rescues normal tissue after high-dose methotrexate and, given with fluorouracil, makes that chemotherapy work better, which is why it appears in FOLFOX, FOLFIRI and FOLFIRINOX.","summary":"Leucovorin (folinic acid, calcium folinate) is a form of folate that cells can use without the enzyme methotrexate blocks. Given after high-dose methotrexate it lets normal bone marrow and gut recover while the drug has already acted on the tumour; given with fluorouracil it increases the drug's binding to its target enzyme thymidylate synthase, an effect that underlies every fluorouracil-based bowel, stomach and pancreatic cancer regimen. Levoleucovorin is the active isomer alone at half the dose. It is a generic medicine on the WHO essential medicines list.","status":"established","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Folinic_acid","links":[{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=leucovorin%20calcium"}],"tags":["gap-fill","generic"],"related":[],"cancers":["colorectal","pancreatic","gastric","all-leukemia"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":["dhfr","tyms"],"drugs":["methotrexate","fluorouracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["int-0116","nct07775287","nct07412613","nct07621718","nct06107413","nct05846867","nct04421820","nct06493760","nct06901531","nct07056777","nct06662786","nct03505320","nct06750094","nct07238283","nct06703177","nct05859750","nct04919226"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Wellcovorin / generic","modality":"Reduced folate (rescue agent and chemotherapy modulator)","supportive":true,"mechanism":"A reduced folate that bypasses dihydrofolate reductase, rescuing normal cells from methotrexate, and that stabilises the fluorouracil-thymidylate synthase complex to make fluorouracil more effective.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/leucovorin/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/"}],"target":[{"id":"dhfr","kind":"target","name":"Dihydrofolate reductase (DHFR)","route":"/targets/dhfr/"},{"id":"tyms","kind":"target","name":"Thymidylate synthase (TYMS)","route":"/targets/tyms/"}],"drug":[{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/"},{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/"}],"trial":[{"id":"nct06887218","kind":"trial","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06887218/"},{"id":"nct07585279","kind":"trial","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","route":"/trials/nct07585279/"},{"id":"nct06493760","kind":"trial","name":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","route":"/trials/nct06493760/"},{"id":"nct05846867","kind":"trial","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","route":"/trials/nct05846867/"},{"id":"nct05859750","kind":"trial","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","route":"/trials/nct05859750/"},{"id":"nct06750094","kind":"trial","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","route":"/trials/nct06750094/"},{"id":"nct06662786","kind":"trial","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","route":"/trials/nct06662786/"},{"id":"nct07737600","kind":"trial","name":"A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer","route":"/trials/nct07737600/"},{"id":"nct06703177","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","route":"/trials/nct06703177/"},{"id":"nct03505320","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","route":"/trials/nct03505320/"},{"id":"nct06901531","kind":"trial","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","route":"/trials/nct06901531/"},{"id":"nct07123441","kind":"trial","name":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","route":"/trials/nct07123441/"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/"},{"id":"nct07441369","kind":"trial","name":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","route":"/trials/nct07441369/"},{"id":"nct06531278","kind":"trial","name":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance","route":"/trials/nct06531278/"},{"id":"nct06662877","kind":"trial","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","route":"/trials/nct06662877/"},{"id":"avf2107g","kind":"trial","name":"AVF2107g","route":"/trials/avf2107g/"},{"id":"ballad","kind":"trial","name":"BALLAD","route":"/trials/ballad/"},{"id":"nct04421820","kind":"trial","name":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","route":"/trials/nct04421820/"},{"id":"nct06438822","kind":"trial","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","route":"/trials/nct06438822/"},{"id":"nct00399035","kind":"trial","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","route":"/trials/nct00399035/"},{"id":"nct04068103","kind":"trial","name":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery","route":"/trials/nct04068103/"},{"id":"nct00628810","kind":"trial","name":"Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","route":"/trials/nct00628810/"},{"id":"nct02883049","kind":"trial","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","route":"/trials/nct02883049/"},{"id":"nct00557193","kind":"trial","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","route":"/trials/nct00557193/"},{"id":"combomatch-binimetinib-folfox","kind":"trial","name":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations","route":"/trials/combomatch-binimetinib-folfox/"},{"id":"conko-003","kind":"trial","name":"CONKO-003 (OFF)","route":"/trials/conko-003/"},{"id":"nct07705919","kind":"trial","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","route":"/trials/nct07705919/"},{"id":"eortc-40983","kind":"trial","name":"EORTC 40983","route":"/trials/eortc-40983/"},{"id":"esopec","kind":"trial","name":"ESOPEC","route":"/trials/esopec/"},{"id":"espac-1","kind":"trial","name":"ESPAC-1","route":"/trials/espac-1/"},{"id":"espac-3","kind":"trial","name":"ESPAC-3","route":"/trials/espac-3/"},{"id":"nct06643793","kind":"trial","name":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","route":"/trials/nct06643793/"},{"id":"nct07056777","kind":"trial","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","route":"/trials/nct07056777/"},{"id":"nct05647122","kind":"trial","name":"First in Human Study of AZD9592 in Solid Tumors","route":"/trials/nct05647122/"},{"id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/"},{"id":"nct06780787","kind":"trial","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","route":"/trials/nct06780787/"},{"id":"nct07621497","kind":"trial","name":"FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)","route":"/trials/nct07621497/"},{"id":"nct03678428","kind":"trial","name":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","route":"/trials/nct03678428/"},{"id":"nct00541125","kind":"trial","name":"G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","route":"/trials/nct00541125/"},{"id":"nct00634322","kind":"trial","name":"High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma","route":"/trials/nct00634322/"},{"id":"nct06217042","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06217042/"},{"id":"nct06383078","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06383078/"},{"id":"nct06928584","kind":"trial","name":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","route":"/trials/nct06928584/"},{"id":"int-0116","kind":"trial","name":"INT-0116 (Macdonald trial)","route":"/trials/int-0116/"},{"id":"nct07238283","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct07238283/"},{"id":"nct06172036","kind":"trial","name":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","route":"/trials/nct06172036/"},{"id":"nct06782685","kind":"trial","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","route":"/trials/nct06782685/"},{"id":"nct06184698","kind":"trial","name":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","route":"/trials/nct06184698/"},{"id":"nct07797816","kind":"trial","name":"Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer","route":"/trials/nct07797816/"},{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/"},{"id":"nct07062536","kind":"trial","name":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","route":"/trials/nct07062536/"},{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/"},{"id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/"},{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/"},{"id":"nct04005339","kind":"trial","name":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","route":"/trials/nct04005339/"},{"id":"nct06941857","kind":"trial","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","route":"/trials/nct06941857/"},{"id":"nct07412613","kind":"trial","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","route":"/trials/nct07412613/"},{"id":"netherlands-hipec","kind":"trial","name":"Netherlands Cancer Institute HIPEC trial","route":"/trials/netherlands-hipec/"},{"id":"nife","kind":"trial","name":"NIFE (AIO-YMO HEP-0315)","route":"/trials/nife/"},{"id":"nifty","kind":"trial","name":"NIFTY","route":"/trials/nifty/"},{"id":"nct00002893","kind":"trial","name":"Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer","route":"/trials/nct00002893/"},{"id":"panoptimox-prodige-35","kind":"trial","name":"PANOPTIMOX-PRODIGE 35","route":"/trials/panoptimox-prodige-35/"},{"id":"nct07214298","kind":"trial","name":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07214298/"},{"id":"nct06210360","kind":"trial","name":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","route":"/trials/nct06210360/"},{"id":"petacc-3","kind":"trial","name":"PETACC-3","route":"/trials/petacc-3/"},{"id":"nct06341296","kind":"trial","name":"Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct06341296/"},{"id":"nct07271355","kind":"trial","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","route":"/trials/nct07271355/"},{"id":"prodige-4-accord-11","kind":"trial","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/"},{"id":"prodige-7","kind":"trial","name":"PRODIGE 7","route":"/trials/prodige-7/"},{"id":"quasar","kind":"trial","name":"QUASAR","route":"/trials/quasar/"},{"id":"nct00057811","kind":"trial","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","route":"/trials/nct00057811/"},{"id":"nct07150403","kind":"trial","name":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal","route":"/trials/nct07150403/"},{"id":"nct07025174","kind":"trial","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","route":"/trials/nct07025174/"},{"id":"nct07831993","kind":"trial","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","route":"/trials/nct07831993/"},{"id":"nct07775287","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","route":"/trials/nct07775287/"},{"id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/"},{"id":"nct06107413","kind":"trial","name":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese","route":"/trials/nct06107413/"},{"id":"nct02885753","kind":"trial","name":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C","route":"/trials/nct02885753/"},{"id":"nct00660894","kind":"trial","name":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","route":"/trials/nct00660894/"},{"id":"nct06958328","kind":"trial","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct06958328/"},{"id":"nct05863195","kind":"trial","name":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","route":"/trials/nct05863195/"},{"id":"nct05610163","kind":"trial","name":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage","route":"/trials/nct05610163/"},{"id":"nct05628038","kind":"trial","name":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","route":"/trials/nct05628038/"},{"id":"nct06490536","kind":"trial","name":"The Sagittarius Trial","route":"/trials/nct06490536/"},{"id":"nct04094688","kind":"trial","name":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct04094688/"},{"id":"nct02022358","kind":"trial","name":"Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?","route":"/trials/nct02022358/"}],"paper":[{"id":"paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007","kind":"paper","name":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)","route":"/key-papers/paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007/"},{"id":"paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021","kind":"paper","name":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7)","route":"/key-papers/paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021/"},{"id":"paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990","kind":"paper","name":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","route":"/key-papers/paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990/"},{"id":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","kind":"paper","name":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","route":"/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/"},{"id":"paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003","kind":"paper","name":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","route":"/key-papers/paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003/"}]}}